Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tolerability and safety aspects of mirtazapine.

Nutt DJ.

Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S37-41. Review.

PMID:
12404669
3.

Tolerability and patient compliance.

Roose SP.

J Clin Psychiatry. 1999;60 Suppl 17:14-7; discussion 46-8. Review.

PMID:
10446736
4.

Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.

Nutt DJ.

Depress Anxiety. 1998;7 Suppl 1:7-10. Review.

PMID:
9597345
5.

Pharmacology of antidepressants: selectivity or multiplicity?

Westenberg HG.

J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. Review.

PMID:
10446734
6.

The pharmacologic profile of mirtazapine.

de Boer T.

J Clin Psychiatry. 1996;57 Suppl 4:19-25. Review.

PMID:
8636062
7.

Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects.

Stimmel GL, Dopheide JA, Stahl SM.

Pharmacotherapy. 1997 Jan-Feb;17(1):10-21. Review.

PMID:
9017762
8.

Mirtazapine: a newer antidepressant.

Hartmann PM.

Am Fam Physician. 1999 Jan 1;59(1):159-61. Review.

9.

A review of the pharmacological and clinical profile of mirtazapine.

Anttila SA, Leinonen EV.

CNS Drug Rev. 2001 Fall;7(3):249-64. Review.

10.

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

de Boer T.

Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. Review. Erratum in: Int Clin Psychopharmacol 1996 Jun;11(2):153.

PMID:
8930006
11.

Mirtazapine: clinical overview.

Gorman JM.

J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Review.

PMID:
10446735
12.

Antidepressant treatment of the depressed patient with insomnia.

Thase ME.

J Clin Psychiatry. 1999;60 Suppl 17:28-31; discussion 46-8. Review.

PMID:
10446739
13.

The use of mirtazapine in difficult-to-treat patient populations.

Hirschfeld RM.

Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S33-6. Review.

PMID:
12404668
14.

Onset of action of antidepressants: results of different analyses.

Thompson C.

Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S27-32. Review.

PMID:
12404667
15.

Mirtazapine: clinical advantages in the treatment of depression.

Burrows GD, Kremer CM.

J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. Review.

PMID:
9090576
16.
17.

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.

Haddjeri N, Blier P, de Montigny C.

Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:11-7. Review. Erratum in: Int Clin Psychopharmacol 1996 Jun;11(2):153.

PMID:
8930005
18.

Tolerability and safety: essentials in antidepressant pharmacotherapy.

Lader MH.

J Clin Psychiatry. 1996;57 Suppl 2:39-44. Review.

PMID:
8626362
19.

Mirtazapine: a review of its clinical efficacy and tolerability.

Szegedi A, Schwertfeger N.

Expert Opin Pharmacother. 2005 Apr;6(4):631-41. Review. No abstract available.

PMID:
15934889
20.

[Two new antidepressants: mirtazapine and venlafaxine].

Birkenhäger TK, Moleman P.

Ned Tijdschr Geneeskd. 1999 May 1;143(18):934-7. Review. Dutch.

PMID:
10368708

Supplemental Content

Support Center